Source-grounded facts extracted from REPLIGEN CORP's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
REPLIGEN CORP shareholders approved Advisory Vote on Compensation of the Named Executive Officers at the 2026-05-14 meeting.
“Proposal 3 - Advisory Vote on Compensation of the Named Executive Officers For Against Abstain Broker Non-Votes 50,333,558 1,513,515 51,173 2,124,113”
REPLIGEN CORP shareholders approved Ratification of the Appointment of Independent Registered Public Accounting Firm at the 2026-05-14 meeting.
“Proposal 2 - Ratification of the Appointment of Independent Registered Public Accounting Firm For Against Abstain Broker Non-Votes 53,092,462 900,084 29,813 —”
REPLIGEN CORP shareholders approved Election of nine director nominees to the Board of Directors at the 2026-05-14 meeting.
“Proposal 1 - Election of the Board of Directors Nominee For Against Abstain Broker Non-Votes Olivier Loeillot 51,750,665 116,198 31,383 2,124,113 Martin Madaus, D.V.M., Ph.D. 51,091,036 775,295 31,915 2,124,113 Karen A. Dawes 42,726,647 9,132,553 39,046 2,124,113 Nicolas M. Barthelemy 51,526,602 339,481 32,163 2,124,113 Carrie Eglinton Manner 41,987,697 9,871,020 39,529 2,124,113 Konstantin Konstantinov, Ph.D. 51,137,462 728,874 31,910 2,124,113 Rohin Mhatre, Ph.D. 51,649,920 215,384 32,942 2,124,113 Glenn P. Muir 38,592,456 13,265,484 40,306 2,124,113 Margaret A. Pax 51,011,846 849,103 37,297 2,124,113”
REPLIGEN CORP reported first quarter ended March 31, 2026 results: revenue $194 million, EPS $0.15. Guidance reaffirmed.
“#1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports First Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance • First quarter revenue of $194 million, a year-over-year increase of 15% as reported and 11% organic • GAAP EPS increased 50% year-over-year and adjusted EPS increased 23% year-over-year • Reiterating FY26 organic”
Karen A. Dawes was appointed as Lead Independent Director at REPLIGEN CORP.
“appointed Karen A. Dawes, the Board’s current Chair, to the role of Lead Independent Director”
Tony J. Hunt changed role as Executive Chair at REPLIGEN CORP.
“Tony J. Hunt, who will serve as Executive Chair of the Repligen board of directors”
Olivier Loeillot was elected as Member of the Board at REPLIGEN CORP.
“the Board elected Mr. Loeillot as a member of the Board”
Olivier Loeillot was appointed as President and Chief Executive Officer at REPLIGEN CORP.
“Repligen has appointed Olivier Loeillot, Repligen’s President and Chief Commercial Officer, to the role of President and Chief Executive Officer, as successor to Tony J. Hunt, who will serve as Executive Chair of the Repligen board of directors (the “Board”), with such transition to be effective September 1, 2024”
REPLIGEN CORP shareholders approved Advisory Vote on Compensation of the Named Executive Officers at the 2024-05-16 meeting.
“The results of the vote were as follows: FOR AGAINST ABSTAIN BROKER NON-VOTES NUMBER 46,636,342 2,832,814 66,253 3,335,291”
REPLIGEN CORP shareholders approved Ratify the Appointment of Independent Registered Public Accounting Firm at the 2024-05-16 meeting.
“The results of the ratification were as follows: FOR AGAINST ABSTAIN BROKER NON-VOTES NUMBER 50,203,147 2,635,812 31,741 0”
REPLIGEN CORP shareholders approved Election of nine directors at the 2024-05-16 meeting.
“The results of the election were as follows: NOMINEE FOR AGAINST ABSTAIN BROKER NON-VOTES Tony J. Hunt 49,451,347 34,608 49,454 3,335,291 Karen A. Dawes 46,716,865 2,770,270 48,274 3,335,291 Nicolas M. Barthelemy 47,873,168 1,612,070 50,171 3,335,291 Carrie Eglinton Manner 49,392,147 95,997 47,265 3,335,291 Konstantin Konstantinov, Ph.D. 48,360,681 1,124,367 50,361 3,335,291 Martin Madaus, D.V.M., Ph.D. 45,950,040 3,534,764 50,605 3,335,291 Rohin Mhatre, Ph.D. 49,290,001 195,180 50,228 3,335,291 Glenn P. Muir 48,280,711 1,204,396 50,302 3,335,291 Margaret A. Pax 49,475,139 12,749 47,521 3,335,291”
REPLIGEN CORP reported first quarter of 2024, covering the three-month period ended March 31, 2024 results: revenue $151.3 million, net income $2.1 million, EPS $0.04. Guidance reaffirmed.
“Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports First Quarter 2024 Financial Results • Reports first quarter revenue of $151 million • Increased new modalities revenue by 16% year-over-year • Increased Filtration (non-COVID) revenue by 12% year-over-year • Achieved a nine-month book-to-bill ratio of 1.03”
Margaret A. Pax was elected as Director at REPLIGEN CORP.
“the Board elected Margaret A. Pax to the Board, effective immediately (the “Effective Date”).”
REPLIGEN CORP reported financial results for the fourth quarter and year end December 31, 2023.
“On February 21, 2024, Repligen Corporation announced its financial results for the fourth quarter and year end December 31, 2023.”
REPLIGEN CORP incurred senior notes of $600 million aggregate principal amount with Wilmington Trust, National Association at 1.00% per annum maturing December 15, 2028.
“On December 14, 2023, in connection with the consummation of previously announced private exchange and subscription transactions, Repligen Corporation (the “Company”) issued $600 million aggregate principal amount of its 1.00% Convertible Senior Notes due 2028 (the “New Notes”) under an Indenture, dated December 14, 2023 (the “Indenture”), between the Company and Wilmington Trust, National Association, as trustee.”
REPLIGEN CORP entered into Indenture with Wilmington Trust, National Association, as trustee valued at $600 million aggregate principal amount (effective 2023-12-14).
“On December 14, 2023, in connection with the consummation of previously announced private exchange and subscription transactions, Repligen Corporation (the "Company") issued $600 million aggregate principal amount of its 1.00% Convertible Senior Notes due 2028 (the "New Notes") under an Indenture, dated December 14, 2023 (the "Indenture"), between the Company and Wilmington Trust, National Association, as trustee.”
REPLIGEN CORP reported fiscal year 2023 results: revenue $635M-$645M, net income $72M-$75M, EPS $1.26-$1.32. Guidance lowered.
“Our financial guidance for the fiscal year 2023 is based on expectations for our existing business. Our GAAP and Adjusted (non-GAAP) guidance includes the impact of our FlexBiosys and Metenova acquisitions and excludes the impact of potential additional acquisitions, and future fluctuations in foreign currency exchange rates. CURRENT GUIDANCE (at October 31, 2023) PRIOR GUIDANCE (at August 2, 2023) FY 2023 GAAP Adjusted (Non-GAAP) GAAP Adjusted (Non-GAAP) Total Reported Revenue $635M-$645M $635M-$645M $635M-$665M $635M-$665M”
REPLIGEN CORP reported third quarter ended September 30, 2023 results: revenue $141.2 million, net income $18.2 million, EPS $0.32.
“100 Waltham, Massachusetts 02453 Repligen Reports Third Quarter 2023 Financial Results and Updates Full Year 2023 Financial Guidance • Reports total third quarter revenues of $141.2 million, with base business revenues of $140.1 million • Orders strengthened with total book-to-bill ratio of 1.07 • Narrows full year revenue guidance to range of $635-$645 million”
Tony Hunt changed role as President at REPLIGEN CORP.
“In connection with Mr. Hunt’s and the rest of the Board’s appointment of Mr. Loeillot’s as President and Chief Commercial Officer, Mr. Hunt will relinquish his role of President, effective October 2, 2023.”
Olivier Loeillot was appointed as President and Chief Commercial Officer at REPLIGEN CORP.
“On October 2, 2023, Repligen Corporation (the “Company”) announced that Olivier Loeillot would be joining the Company as its President and Chief Commercial Officer, effective October 2, 2023 (the “Effective Date”).”
Jon Snodgres retired as Chief Financial Officer at REPLIGEN CORP.
“replacing Jon Snodgres, who tendered his intention to retire on September 8, 2023 and who will continue in a full-time advisory role with the Company until October 6, 2023.”
Jason K. Garland was appointed as Chief Financial Officer at REPLIGEN CORP.
“On September 12, 2023, Repligen Corporation (the “Company”) announced that Jason K. Garland would be joining the Company as its Chief Financial Officer, effective September 25, 2023 (the “Effective Date”), replacing Jon Snodgres, who tendered his intention to retire on September 8, 2023 and who will continue in a full-time advisory role with the Company until October 6, 2023.”
REPLIGEN CORP reported fiscal year 2023 results: revenue $635-$665 million. Guidance lowered.
“Total reported revenue is expected to be in the range of $635-$665 million, compared to our previous guidance of $720-$760 million.”
REPLIGEN CORP reported second quarter ended June 30, 2023 results: revenue $159.2 million, net income $20.1 million, EPS $0.35. Guidance lowered.
“Suite 100 Waltham, Massachusetts 02453 Repligen Reports Second Quarter 2023 Financial Results and Updates Full Year 2023 Financial Guidance • Reports second quarter revenues of $159.2 million as reported, and base business revenues of $157.1 million, down 9% year-over-year • Adjusts full year revenue guidance to range of $635-$665 million WALTHAM, Mass., August 02,”
REPLIGEN CORP: Amendment to Certificate of Incorporation to permit Board to adopt, amend or repeal Bylaws (effective 2023-05-18).
“Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. As described below in Item 5.07 of this Current Report on Form 8-K and in Repligen Corporation’s (the “Company”) proxy statement filed with the Securities and Exchange Commission under Section 14(a) of the Securities Exchange Act, as amended, on April 11, 2023 (the “Proxy Statement”), on May 18, 2023, the Company’s shareholders voted at the Company’s 2023 annual meeting of shareholders (the “Annual Meeting”) to, among other things, approve an amendment (the “Charter Amendment”) to the Company’s Certificate of Incorporation to permit the Board of Directors of the Company (the “Board”) to adopt, amend or repeal the Company’s By-laws.”
REPLIGEN CORP shareholders approved Approve the Ratification of the Amendment and Restatement of the By-laws to implement shareholder proxy access at the 2023-05-18 meeting.
“Proposal 6 – Approve the Ratification of the Amendment and Restatement of the By-laws The ratification of the amendment and restatement of the By-laws adopted by the Board on January 27, 2021 to implement shareholder proxy access was ratified. The results of the ratification were as follows: FOR AGAINST ABSTAIN BROKER NON-VOTES NUMBER 49,551,765 19,487 40,088 2,990,083”
REPLIGEN CORP shareholders approved Approve the Charter Amendment to permit the Board to adopt, amend or repeal the By-laws at the 2023-05-18 meeting.
“Proposal 5 - Approve the Charter Amendment The amendment to the Company's Certificate of Incorporation to permit the Board to adopt, amend or repeal the By-laws was approved. The results of the vote were as follows: FOR AGAINST ABSTAIN BROKER NON-VOTES NUMBER 42,247,296 6,615,716 748,328 2,990,083”
REPLIGEN CORP shareholders approved Advisory Vote on Frequency of Future Advisory Votes on the Compensation of Named Executive Officers at the 2023-05-18 meeting.
“Proposal 4 – Advisory Vote on Frequency of Future Advisory Votes on the Compensation of Named Executive Officers The frequency of future advisory votes on the compensation of the Company's named executive officers was approved on advisory basis. The results of the vote were as follows: 1 Year 2 Years 3 Years ABSTAIN BROKER NON-VOTES NUMBER 49,248,032 32,822 287,871 42,615 2,990,083”
REPLIGEN CORP shareholders approved Advisory Vote on Compensation of the Named Executive Officers at the 2023-05-18 meeting.
“Proposal 3 - Advisory Vote on Compensation of the Named Executive Officers The compensation paid to the Company's named executive officers was approved on an advisory basis. The results of the vote were as follows: FOR AGAINST ABSTAIN BROKER NON-VOTES NUMBER 48,195,853 1,375,453 40,034 2,990,083”
REPLIGEN CORP shareholders approved Ratify the Appointment of Independent Registered Public Accounting Firm at the 2023-05-18 meeting.
“Proposal 2 - Ratify the Appointment of Independent Registered Public Accounting Firm The appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023 was ratified. The results of the ratification were as follows: FOR AGAINST ABSTAIN BROKER NON-VOTES NUMBER 51,821,932 754,809 24,682 0”
REPLIGEN CORP shareholders approved Election of the Board of Directors at the 2023-05-18 meeting.
“Proposal 1 - Election of the Board of Directors Nicolas M. Barthelemy, Karen A. Dawes, Carrie Eglinton Manner, Tony J. Hunt, Rohin Mhatre, Ph.D., Glenn P. Muir, Konstantin Konstantinov, Ph.D. and Martin Madaus, D.V.M., Ph.D. were duly elected to the Board. The results of the election were as follows: NOMINEE FOR AGAINST ABSTAIN BROKER NON-VOTES Nicolas M. Barthelemy 46,619,756 2,954,456 37,128 2,990,083 Karen A. Dawes 44,258,984 5,315,967 36,389 2,990,083 Carrie Eglinton Manner 49,411,646 163,031 36,663 2,990,083 Tony J. Hunt 49,421,145 153,400 36,795 2,990,083 Rohin Mhatre, Ph.D. 48,929,182 641,737 40,421 2,990,083 Glenn P. Muir 48,828,381 745,628 37,331 2,990,083 Konstantin Konstantinov, Ph.D. 47,615,575 1,958,323 37,442 2,990,083 Martin Madaus, D.V.M., Ph.D. 48,627,119 946,461 37,760 2,990,083”
REPLIGEN CORP reported first quarter ended March 31, 2023 results: revenue $182.7 million, net income $28.8 million, EPS $0.51. Guidance lowered.
“REVENUE • Total revenue for the first quarter of 2023 was $182.7 million compared to $206.4 million for the first quarter of 2022, a year-over-year decrease of 12% as reported, and down 9% at constant currency. GROSS PROFIT and GROSS MARGIN • Gross profit (GAAP) for the first quarter of 2023 was $100.8 million compared to $124.0 million for the first quarter of 2022. Adjusted gross profit (non-GAAP) for the first quarter of 2023 was $100.8 million, a decrease of 19% compared to $124.6 million for the first quarter of 2022. • Gross margin (GAAP) for the first quarter of 2023 was 55.2%, compared to 60.1% for the first quarter of 2022. Adjusted gross margin (non-GAAP) for the first quarter was 55.2%, compared to 60.4% in the 2022 period, a year-over-year decrease of approximately 520 basis points. INCOME FROM OPERATIONS • Income from operations (GAAP) for the first quarter of 2023 was $31.3 million, compared to $60.0 million for the first quarter of 2022. Our GAAP income from operations f”
REPLIGEN CORP reported financial results for the fourth quarter and year end December 31, 2022.
“On February 22, 2023, Repligen Corporation announced its financial results for the fourth quarter and year end December 31, 2022.”
Martin Madaus was elected as Director at REPLIGEN CORP.
“the Board elected Martin Madaus, Ph.D. to the Board, effective February 6, 2023”
REPLIGEN CORP reported the year 2022 results: revenue $795-$805 million.
“YEAR 2022 GUIDANCE: • Total reported revenue is expected to be in the range of $795-$805 million, compared to our previous guidance of $790-$810 million.”
REPLIGEN CORP reported the third quarter ended September 30, 2022 results: revenue $200.7 million, net income $40.4 million, EPS $0.71 on a fully diluted basis.
“Total revenue as reported for the third quarter of 2022 increased to $200.7 million compared to $178.2 million for the third quarter of 2021, a year-over-year gain of 13%, or 19% at constant currency, and organic growth of 16%.”
Konstantin Konstantinov was elected as Director at REPLIGEN CORP.
“the Board elected Konstantin Konstantinov, Ph.D. to the Board, effective May 26, 2022”
James Bylund changed role as Chief Operating Officer at REPLIGEN CORP.
“On January 3, 2022, Repligen Corporation (the “ Company ”) promoted James Bylund, the Company’s current Senior Vice President, Operations and Information Technologies, to the role of Chief Operating Officer of the Company, effective January 1, 2022.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.